CHCWM – Cancer & Hematology Centers of West Michigan

GS-US-496-5657 (Gilead)

Phase 1b Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS-3583, a FLT3 agonist Fc fusion protein, in Subjects with Advanced Solid Tumors